Home DNA Damage/DNA Repair DNA/RNA Synthesis inhibitor Cidofovir

research use only

Cidofovir DNA/RNA Synthesis inhibitor

Cat.No.S1516

Cidofovir suppresses virus replication by selective inhibition of viral DNA synthesis.
Cidofovir DNA/RNA Synthesis inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 279.19

Jump to

Quality Control

Batch: Purity: 99.97%
99.97

Cell Culture, Treatment & Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEL cells Function assay Compound was tested for anti-viral activity against HSV-1(KOS) in HEL cells, EC50=0.57 μM
MRC-5 cells Function assay Inhibitory activity against cytopathic effect of HSV-2(E 194) in MRC-5 cells, IC50=10 μM
NHDF cells Function assay Inhibitory activity against replication of HCMV in NHDF cells, IC50=0.5 μM
HFF cells Function assay Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction in cytopathogenicity, EC50=3.2 μM
HFF cells Function assay Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction in cytopathogenicity, EC50=7.1 μM
HFF cells Function assay Antiviral activity against vaccinia virus Copenhagen measured as cytopathogenicity in HFF cells, EC50=6.9 μM
bone marrow cells Cytotoxicity assay Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage, IC50=10 μM
HFF cells Function assay Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay, IC50=0.3 μM
MRC5 cells Function assay Antiviral activity against Human CMV Towne in MRC5 cells by PRA, IC50=0.3 μM
UC1B cells Function assay Antiviral activity against Murine polyomavirus MN/RDE Toronto in mouse UC1B cells assessed as reduction of virus-induced cytopathogenicity, EC50=13 μM
african green monkey Vero cells Function assay Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50=14.4 μM
HEL cells Function assay 3 days Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days, EC50=0.41 μM
HEL cells Function assay 3 days Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days, EC50=0.41 μM
HFF cells Function assay Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay, EC50=0.22 μM
HEL cells Function assay Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50=0.74 μM
HEL cells Function assay Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection, EC50=0.5 μM
HEL cells Function assay Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection, EC50=0.3 μM
HEL cells Function assay Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity, IC50=0.045 μM
HFF Proliferation assay 3 days Antiproliferative activity against HFF after 3 days by coulter counter assay, EC50=1.9 μM
HeLaS3 cells Function assay 3-5 days Antiviral activity against Vaccinia virus IHD-J ATCC VR-156 infected in HeLaS3 cells after 3 to 5 days by plaque assay, EC50=18.74 μM
HSB2 cells Function assay 7 days Antiviral activity against Human herpesvirus 6 GS infected in human HSB2 cells assessed as decrease in viral DNA accumulation after 7 days, EC50=2.7 μM
A549 cells Function assay Antiviral activity against Human adenovirus type 11p slobitski infected in A549 cells assessed as inhibition of DNA replication by QPCR assay, EC50=16.5 μM
HFF cells Function assay Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay, EC50=6.7 μM
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

Water : 3 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 279.19 Formula

C8H14N3O6P

 Storage (From the date of receipt)
CAS No. 113852-37-2 Download SDF Storage of Stock Solutions

Synonyms HPMPC, GS 0504 SMILES C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro

Cidofovir inhibits human cytomegalovirus (HCMV) infection in cultured cells. This compound is inhibitory to CMV plaque formation even when added to the cells at 48 hr post infection with IC50 of 0.9 μg/mL for Davis and 1.6 μg/mL for AD-169 strains,respectively. It also inhibits herpes simplex virus infection. In addition, this chemical blocks cell fusion induced by HSV-1 in monkey kidney cells and blocks the expression of HSV-l-specific proteins and the synthesis of viral DNA.

In vivo

Cidofovir (5 mg/kg/day) subcutaneously for 5 days significantly reduces average virus infectivity titer in blood, spleen, lung and salivary gland in infected guinea pigs. This compound significantly reduces lymphocytosis and average tissue indexe of spleen in infected animals. . It suppresses all manifestations (skin lesions, paralysis of the hind legs, and mortality) of hairless mice infected intracutaneously with HSV-1 or HSV-2. The most remarkable feature of this compound is that a single administration of the compound, even as late as 4 days after infection, conferees significant protection against HSV-1 or HSV-2 infection. This chemical inhibits growth of the highly aggressive melanoma tumor arising from mouse melanoma B16 cells grafted subcutaneously in C57B16/J mice.

References
  • [4] https://pubmed.ncbi.nlm.nih.gov/2069375/
  • [5] https://pubmed.ncbi.nlm.nih.gov/11069450/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-03-06)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01295645 ACTIVE_NOT_RECRUITING
Transplantation Infection
M.D. Anderson Cancer Center
 2011-03-17 PHASE2
NCT07387367 RECRUITING
Adenovirus Infections
SymBio Pharmaceuticals
 2026-03-17 PHASE3
NCT06439342 RECRUITING
Cytomegalovirus (CMV)
Takeda
 2024-12-16 PHASE3
NCT04706923 COMPLETED
Adenovirus Infections; Cytomegalovirus Infection
SymBio Pharmaceuticals
 2021-08-16 PHASE2
NCT04055142 COMPLETED
High-grade Anal Intraepithelial Neoplasia
Hospital Universitari Vall d'Hebron Research Institute
 2020-09-18 PHASE3
NCT04542252 Completed
Drug Drug Interaction
SymBio Pharmaceuticals
 2020-11-09 Phase 1

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map